NASDAQ:IMMY - Imprimis Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $6.68 +0.38 (+6.03 %) (As of 02/21/2019 04:00 PM ET)Previous Close$6.30Today's Range$6.2886 - $6.8952-Week Range$1.45 - $6.50Volume680,137 shsAverage Volume482,230 shsMarket Capitalization$155.51 millionP/E Ratio-11.13Dividend YieldN/ABeta-1.06 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Imprimis Pharmaceuticals, Inc., an ophthalmology-focused pharmaceutical company, engages in the development, production, and sale of medications to physicians and patients in the United States. It offers ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications. The company also develops and commercializes therapeutics for the ocular surface diseases. In addition, it provides patent-pending preservative-free topical eye drop drug candidates, including SURF-100, an immunosuppressive drug that inhibits t-cell proliferation and replication in the dry eye disease (DED); SURF-200 for the patients with episodic DED; and SURF-300, a combination of a low-dose of doxycycline and a proprietary powderized triglyceride Omega-3 for the refractory DED patients with chronic DED symptoms. The company was formerly known as Transdel Pharmaceuticals, Inc. and changed its name to Imprimis Pharmaceuticals, Inc. in February 2012. Imprimis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in San Diego, California. Receive IMMY News and Ratings via Email Sign-up to receive the latest news and ratings for IMMY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IMMY Previous Symbol CUSIPN/A CIK1360214 Webwww.imprimisrx.com Phone858-704-4040Debt Debt-to-Equity Ratio2.84 Current Ratio1.13 Quick Ratio0.88Price-To-Earnings Trailing P/E Ratio-11.13 Forward P/E Ratio9.68 P/E GrowthN/A Sales & Book Value Annual Sales$26.77 million Price / Sales5.81 Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / Book51.38Profitability EPS (Most Recent Fiscal Year)($0.60) Net Income$-11,980,000.00 Net Margins-16.81% Return on Equity-231.16% Return on Assets-25.18%Miscellaneous Employees128 Outstanding Shares23,280,000Market Cap$155.51 million Next Earnings Date3/14/2019 (Estimated) OptionableOptionable Imprimis Pharmaceuticals (NASDAQ:IMMY) Frequently Asked Questions What is Imprimis Pharmaceuticals' stock symbol? Imprimis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IMMY." How were Imprimis Pharmaceuticals' earnings last quarter? Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) released its quarterly earnings results on Monday, August, 6th. The specialty pharmaceutical company reported $0.12 EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.24. The specialty pharmaceutical company earned $10.38 million during the quarter. Imprimis Pharmaceuticals had a negative return on equity of 231.16% and a negative net margin of 16.81%. View Imprimis Pharmaceuticals' Earnings History. When is Imprimis Pharmaceuticals' next earnings date? Imprimis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Imprimis Pharmaceuticals. What price target have analysts set for IMMY? 2 analysts have issued twelve-month target prices for Imprimis Pharmaceuticals' stock. Their forecasts range from $10.00 to $11.50. On average, they anticipate Imprimis Pharmaceuticals' share price to reach $10.75 in the next twelve months. This suggests a possible upside of 60.9% from the stock's current price. View Analyst Price Targets for Imprimis Pharmaceuticals. What is the consensus analysts' recommendation for Imprimis Pharmaceuticals? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Imprimis Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Imprimis Pharmaceuticals. Has Imprimis Pharmaceuticals been receiving favorable news coverage? Press coverage about IMMY stock has been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Imprimis Pharmaceuticals earned a daily sentiment score of 0.6 on InfoTrie's scale. They also gave news headlines about the specialty pharmaceutical company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. Who are some of Imprimis Pharmaceuticals' key competitors? Some companies that are related to Imprimis Pharmaceuticals include CymaBay Therapeutics (CBAY), Basilea Pharmaceutica (BPMUF), Ra Pharmaceuticals (RARX), Synthorx (THOR), Crinetics Pharmaceuticals (CRNX), Karyopharm Therapeutics (KPTI), Akorn (AKRX), Urogen Pharma (URGN), Lexicon Pharmaceuticals (LXRX), ChemoCentryx (CCXI), Kura Oncology (KURA), AMAG Pharmaceuticals (AMAG), Flexion Therapeutics (FLXN), Assembly Biosciences (ASMB) and Aurinia Pharmaceuticals (AUPH). What other stocks do shareholders of Imprimis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Imprimis Pharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Heat Biologics (HTBX), Exelixis (EXEL), Progenics Pharmaceuticals (PGNX), Teva Pharmaceutical Industries (TEVA), Vereit (VER), Gilead Sciences (GILD), NVIDIA (NVDA), Karyopharm Therapeutics (KPTI) and Fate Therapeutics (FATE). Who are Imprimis Pharmaceuticals' key executives? Imprimis Pharmaceuticals' management team includes the folowing people: Mr. Mark L. Baum, Founder, CEO & Director (Age 45)Mr. Andrew R. Boll CFA, CMA, CFO & Corp. Sec. (Age 36)Mr. John P. Saharek, Chief Commercial Officer (Age 58)Mr. David Moufarrège, VP of TechnologyMr. Pramod Sharma Ph.D., VP of Quality Who are Imprimis Pharmaceuticals' major shareholders? Imprimis Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Opaleye Management Inc. (7.40%), Acadian Asset Management LLC (0.66%), Two Sigma Investments LP (0.50%), BlackRock Inc. (0.46%), Barclays PLC (0.24%) and Northern Trust Corp (0.19%). View Institutional Ownership Trends for Imprimis Pharmaceuticals. Which institutional investors are selling Imprimis Pharmaceuticals stock? IMMY stock was sold by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC and Northern Trust Corp. View Insider Buying and Selling for Imprimis Pharmaceuticals. Which institutional investors are buying Imprimis Pharmaceuticals stock? IMMY stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Two Sigma Investments LP, Opaleye Management Inc., Barclays PLC, BlackRock Inc., SVA Plumb Wealth Management LLC and GSA Capital Partners LLP. View Insider Buying and Selling for Imprimis Pharmaceuticals. How do I buy shares of Imprimis Pharmaceuticals? Shares of IMMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Imprimis Pharmaceuticals' stock price today? One share of IMMY stock can currently be purchased for approximately $6.68. How big of a company is Imprimis Pharmaceuticals? Imprimis Pharmaceuticals has a market capitalization of $155.51 million and generates $26.77 million in revenue each year. The specialty pharmaceutical company earns $-11,980,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis. Imprimis Pharmaceuticals employs 128 workers across the globe. What is Imprimis Pharmaceuticals' official website? The official website for Imprimis Pharmaceuticals is http://www.imprimisrx.com. How can I contact Imprimis Pharmaceuticals? Imprimis Pharmaceuticals' mailing address is 12264 El Camino Real Suite 350, San Diego CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-704-4040 or via email at [email protected] MarketBeat Community Rating for Imprimis Pharmaceuticals (NASDAQ IMMY)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 168 (Vote Outperform)Underperform Votes: 161 (Vote Underperform)Total Votes: 329MarketBeat's community ratings are surveys of what our community members think about Imprimis Pharmaceuticals and other stocks. Vote "Outperform" if you believe IMMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMMY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/21/2019 by MarketBeat.com StaffFeatured Article: Do closed-end mutual funds pay dividends?